RPRD Diagnostics Announces Strategic Collaboration with Children's Minnesota to Advance Clinical Pharmacogenomics
MILWAUKEE, Feb. 13, 2017 /PRNewswire/ -- RPRD Diagnostics today announced a collaboration with Children's Minnesota dedicated to implementing a pharmacogenomic testing process. RPRD Diagnostics is a privately-held precision medicine company specializing in comprehensive pharmacogenomics (PGx) testing and analysis. RPRD aims to advance clinical pharmacogenomic testing. By implementing this process the aim is to ensure patients get the right medication at the right time, making care more precise and more affordable.
"Comprehensive pre-emptive pharmacogenomic testing is the cornerstone of precision medicine, especially in pediatrics, and RPRD Diagnostics is a pioneer in this area," said Nancy Mendelsohn, MD, senior medical director of specialty care at Children's Minnesota. "Collaborating with RPRD Diagnostics underscores our commitment to integrating pharmacogenomic medicine into the care of our patients, with the goal of providing better care and better outcomes."
Through this new collaboration, Children's Minnesota will begin using the RPRD Diagnostic platform within the cancer and blood disorder clinic as well as within the neurology-psychology practice. Clinical specialists at the Children's Minnesota genomic medicine program will work closely with RPRD Diagnostics in the implementation of this innovative service.
"We are a science-driven company focused on innovation, and we are excited to work together with Children's Minnesota," said Ulrich Broeckel, MD, founder and CEO of RPRD Diagnostics. "They have made substantial commitments toward implementing pharmacogenomics for their patients and are leading the way as a premiere pediatric healthcare provider. Historically, the application of pharmacogenetics has been limited by the high cost and limited scope of available tests—two barriers that RPRD Diagnostics has overcome. We appreciate that Children's Minnesota sees the value in our comprehensive test panels."
About RPRD Diagnostics
RPRD ('Right Person Right Drug') Diagnostics is dedicated to offering health care providers comprehensive pharmacogenomic testing and analysis services. This information will aid health care providers in their clinical decision-making and help improve patient outcomes. These tests will help physicians make determinations about the safest drug treatment for their patients, taking into account the patient's unique genetic profile against relevant genomic insights and therapeutic approaches. The company's founder, scientific advisors, and technical team are industry leaders in genomics technology, pharmacogenetic testing, and clinical implementation of genetic testing. The company's mission is to enable precision medicine in routine clinical practice. For more information, please visit the company's website at www.rprdx.com, and follow us on Twitter @RPRDx.
About Children's Minnesota
Children's Minnesota is the seventh largest pediatric health system in the United States and the only health system in Minnesota to provide care exclusively to children, from before birth through young adulthood. An independent and not-for-profit system since 1924, Children's serves kids throughout the Upper Midwest at two free-standing hospitals, 12 primary and specialty-care clinics and six rehabilitation sites. Children's maintains its longstanding commitment to the community to improve children's health by providing high-quality, family-centered pediatric services and advancing those efforts through research and education. This work is made possible in large part by generous philanthropic and volunteer support from individuals and organizations throughout the state and region. An award-winning health system, Children's is regularly ranked by U.S. News & World Report as a top children's hospital. Please visit childrensMN.org.
Media Contacts:
Joleen Rau
Rau Communications LLC
(608) 209-0792
[email protected]
SOURCE RPRD (Right Person Right Drug) Diagnostics
Share this article